Data obtained through active surveillance pre and post introduction of PCV in the US showed that the vaccine averted an estimated 38,000 cases of invasive pneumococcal disease within its first five years of use. Additionally, 71,000 cases of disease were estimated to be prevented by herd effects.
Full Citation:
Ray, G.T., Whitney, C., Fireman, B., et al. 2006. Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects. Pediatric Infectious Disease Journal. 25(6).
Title of Article: Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects
Author(s): Ray, G.T., Whitney, C., Fireman, B., et al
Publication Year: 2006
Publication Name: Pediatric Infectious Disease Journal
Publication Volume: 25(6)
Publication Source URL: https://pubmed.ncbi.nlm.nih.gov/16732146/
DOI (Digital Object Identifier): 10.1097/01.inf.0000222403.42974.8b
Topics: Health
Disease Vaccines: Pneumococcal disease/PCV/PPSV | Pneumonia
Countries: United States
WHO Regions: Americas